Table 2 Distribution and statistical comparison of HPV18 lineages between the AA and E lineages
From: Fifteen new nucleotide substitutions in variants of human papillomavirus 18 in Korea
AA(n = 89) | E(n = 8) | P value | ||
|---|---|---|---|---|
Age, years | 46 (40–54) | 58 (47–63) | 0.344* | |
Cervical lesion, n | Grouping | |||
 Normal | ①| 22 (24.7%) | 3 (37.5%) | 0.298†|
 ASCUS | ② | 5 (5.6%) | 2 (25.0%) | |
  LSIL/CIN1 | ③ | 34 (38.2%) | 1 (12.5%) | |
 HSIL/CIN2&3 | ④ | 17 (19.1%) | 1 (12.5%) | |
 Cancer | ⑤ | 11 (12.4%) | 1 (12.5%) | |
Pathology and treatment, n | ||||
 Cancer | ⑤ | 11 (12.4%) | 1 (12.5%) | 1.000‡ |
 Non-cancer | ① + ② + ③ + ④ | 78 (87.6%) | 7 (87.5%) | |
 Surgery | ④ + ⑤ | 28 (31.5%) | 2 (25.0%) | 1.000‡ |
 Observation | ① + ② + ③ | 61 (68.5%) | 6 (75.0%) | |
 Definite dysplasia | ③ + ④ + ⑤ | 62 (69.7%) | 3 (37.5%) | 0.110‡ |
 Normal and ASCUS | ① + ② | 27 (30.3%) | 5 (62.5%) | |
Evidence of co-infection, n | ||||
 With other risk type(s) | 21 (23.6%) | 2 (25.0%) | 1.000‡ | |
 With other high-risk type(s) | 16 (18.0%) | 1 (12.5%) | 1.000‡ | |
§Serial follow-up testing (n = 54) | ||||
Progression (n) | n = 50 | n = 4 | ||
  Progression | 21 (42.0%) | 1 (25.0%) | 0.773‡ | |
  No progression | 29 (58.0%) | 3 (75.0%) | ||